Education
About Us
Working with TipRanks
Follow Us
Iridex Corp (IRIX)
NASDAQ:IRIX
IRIX Stock Chart & Stats
$1.23
-$0.02(-1.39%)
At close: 4:00 PM EST
$1.23
-$0.02(-1.39%)
Day’s Range― - ―
52-Week Range$0.78 - $1.65
Previous CloseN/A
Volume8.51K
Average Volume (3M)66.91K
Market Cap
$24.58M
Enterprise Value$23.45M
Total Cash (Recent Filing)$5.57M
Total Debt (Recent Filing)$4.79M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Mar 05, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding17,189,981
10 Day Avg. Volume69,445
30 Day Avg. Volume66,914
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)13.17
Price to Sales (P/S)0.57
P/FCF Ratio-3.78
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue0.46
Enterprise Value/Gross Profit1.22
Enterprise Value/Ebitda-7.29
Forecast
1Y Price Target
$3.00Price Target Upside143.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Service RevenueIridex's business model includes recurring sales of disposables and service contracts, creating steady, repeatable revenue that smooths capital-equipment cycles. Over the medium term this supports margins and predictability, improving cash visibility versus pure capital-equipment sales.
Product Demand In Glaucoma And Probe Attach RatesSustained unit growth in the Cyclo G6 and high probe volumes indicate strong product-market fit and an attractive attach-rate business. Durable demand for systems plus consumable probes underpins recurring revenue and supports long-term adoption and clinical incumbency in glaucoma care.
Cost Discipline And Path To Cash-flow PositiveManagement's sustained cost reductions and EBITDA improvement reflect operational leverage that can materially improve cash generation. If realized, these structural expense and manufacturing changes reduce liquidity risk and increase runway, making the business more self-sustaining over the next 12–24 months.
Bears Say
Multi-year Revenue Decline And Margin CompressionA persistent revenue decline and shrinking gross margins erode the company's ability to invest in R&D and commercial expansion. Over several quarters this trend signals competitive pressure or demand weakness, making sustained profitability harder without structural product or market-share gains.
Severely Weakened Balance Sheet And Equity ErosionDramatic equity erosion leaves limited financial cushion against shocks and increases leverage. A thin equity base constrains strategic flexibility, raises refinancing and covenant risk, and can force dilutive financing or cost-cutting that undermines long-term competitive positioning.
Negative Operating And Free Cash FlowPersistent negative cash generation undermines sustainability and forces dependence on external financing or dilution. Even with planned improvements, ongoing negative cash flow reduces capacity for capex, marketing, and R&D investments necessary to drive durable growth and defend market share.
Iridex News
IRIX FAQ
What was Iridex Corp’s price range in the past 12 months?
Iridex Corp lowest stock price was $0.78 and its highest was $1.65 in the past 12 months.
What is Iridex Corp’s market cap?
Iridex Corp’s market cap is $24.58M.
When is Iridex Corp’s upcoming earnings report date?
Iridex Corp’s upcoming earnings report date is Mar 05, 2026 which is today.
How were Iridex Corp’s earnings last quarter?
Currently, no data Available
Is Iridex Corp overvalued?
According to Wall Street analysts Iridex Corp’s price is currently Undervalued.
Does Iridex Corp pay dividends?
Iridex Corp does not currently pay dividends.
What is Iridex Corp’s EPS estimate?
Iridex Corp’s EPS estimate is -0.02.
How many shares outstanding does Iridex Corp have?
Iridex Corp has 17,189,981 shares outstanding.
What happened to Iridex Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Iridex Corp?
Currently, no hedge funds are holding shares in IRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Iridex Corp
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
IRIX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and successful cost-cutting measures leading to improved adjusted EBITDA and projections for positive cash flow. However, challenges such as a decrease in gross margin and market difficulties in Asia tempered the overall positive outlook.View all IRIX earnings summariesIRIX Stock 12 Month Forecast
Average Price Target
$3.00
▲(143.90% Upside)
Technical Analysis
Sintx Technologies
―
PAVmed
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Envoy Medical
―
Ownership Overview
10.82% Insiders
3.65% Mutual Funds
8.23% Other Institutional Investors
74.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---